Diane Reidy Lagunes, MD

home / authors / diane-reidy-lagunes-md

Articles

Dr. Lagunes on the Importance of Developing More Personalized Treatments in NETs

February 16th 2018

Diane Reidy Lagunes, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the necessity of tailored approaches in the treatment of patients with neuroendocrine tumors (NETs).

Dr. Lagunes on Potential Combinations in the Treatment of Patients With NETs

Diane Reidy Lagunes, MD

February 3rd 2018

Diane Reidy Lagunes, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses ongoing clinical trials and recent approvals that will shape the standard of care in the treatment of patients with neuroendocrine tumors (NETs).

Dr. Reidy-Lagunes on FDA Approval of Telotristat Ethyl for Carcinoid Syndrome

Diane Reidy Lagunes, MD

March 1st 2017

Diane Reidy-Lagunes, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the FDA approval of telotristat ethyl (Xermelo) as a treatment for carcinoid syndrome in patients with metastatic neuroendocrine tumors (NETs).

Dr. Reidy-Lagunes on Sequencing Therapies for Patients With NETs

Diane Reidy Lagunes, MD

September 28th 2016

Diane Reidy-Lagunes, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses sequencing various treatments for patients with neuroendocrine tumors (NETs).

Dr. Reidy Lagunes on the Potential of Immunotherapy in NETs

Diane Reidy Lagunes, MD

October 21st 2015

Diane Reidy Lagunes, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the potential of immunotherapy agents in the treatment of patients with neuroendocrine carcinoma.

Dr. Reidy-Lagunes on Determining the Site of Unknown Primary in Metastatic NETs

Diane Reidy Lagunes, MD

October 10th 2014

Diane Reidy-Lagunes, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses an analysis looking at a practical method of determining the site of unknown primary in metastatic neuroendocrine tumors (NETs).